Guangyong Peng, M.D., Ph.D.
Guangyong Peng, M.D., Ph.D. is Associate Professor of Immunobiology and Internal Medicine at Saint Louis University School of Medicine. He obtained his medical degree at Jiangsu University and his Ph.D. of Immunology from the Chinese Academy of Preventive Medicine in China. He completed his postdoctoral training in tumor immunology at Baylor College of Medicine. Dr. Peng has been a faculty member at Saint Louis University School of Medicine, since September 1, 2007. Dr. Peng and his research group seek to understand how host immune systems respond to cancer cells and to develop effective vaccines against human cancers.
Malignant tumors create an immunosuppressive microenvironment mediated by regulatory tumor-infiltrating lymphocytes (TILs ) which can prevent effective anti-tumor immunity. A major research interest in Dr. Peng’s Lab is focused on identifying the roles of different types of tumor-associated regulatory T cells (Tregs) in suppression of anti-tumor immunity. His work is contributing to a better understanding of the mechanisms involved in immunopathogenesis, generation, and immune suppression of these Tregs in the tumor microenvironment using in vitro and in vivo models. A second major area of interest in his lab involves the development of strategies to overcome tumor suppressive microenvironments induced by Tregs and tumor cells using Toll-like receptor (TLR) ligands and other immunomodulators. The combined knowledge resulting from these novel studies will potentially lead to the development of more effective vaccines and/or immunotherapies active against human cancers. In addition to his work towards development of cancer vaccines/immunotherapies, he also has begun to investigate the importance of Tregs during infections with chronic intracellular pathogens, such as Mycobacterium tuberculosis.